Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1196 articles by Jacob Bell
-
Sage braces for make-or-break depression data
May 4, 2021 -
Wall Street fears Amgen's tough first quarter is just the start
April 28, 2021 -
Under pressure, Biogen will allow some patients early access to experimental ALS drug
April 27, 2021 -
Vertex moves pain drug into mid-stage testing
April 26, 2021 -
As review of its Alzheimer's drug wraps up, Biogen prepares for an uncertain launch
April 22, 2021 -
With money pouring into biotech, Versant raises another $950M
April 21, 2021 -
The next 2 months in biotech and pharma will be busy. Here's what to watch.
April 20, 2021 -
Vertex bets another $900M on CRISPR treatment for blood diseases
April 20, 2021 -
FDA faces backlash after seeking more data on an experimental ALS therapy
April 14, 2021 -
Gilead stops Veklury study, citing enrollment challenges, changing treatment
April 13, 2021 -
Provention Bio latest drugmaker flagged for 'deficiencies' in FDA approval application
April 9, 2021 -
Biogen adds a late-stage prospect to its growing biosimilar business
April 8, 2021 -
New data push a biotech's muscle disease drug closer to a key test
April 6, 2021 -
Acadia, with drug application rejected, calls out FDA for backtracking
April 5, 2021 -
FDA advisers reassert case against approval of Biogen's Alzheimer's drug
March 31, 2021 -
A biotech shelves its Huntington's drugs after trial failures
March 30, 2021 -
5 FDA approval decisions to watch in the second quarter
March 29, 2021 -
Pfizer and Lilly's pain drug hits setback in negative committee vote
March 26, 2021 -
Drugmakers flock to Vineti's fix for a cell, gene therapy problem
March 24, 2021 -
José Baselga, prominent cancer researcher, dies at 61
March 22, 2021 -
AbbVie's approval delay raises further concerns about JAK drugs
March 18, 2021 -
Global Blood takes on more sickle cell drugs through Sanofi deal
March 16, 2021 -
Gilead, Merck combine forces in HIV
March 15, 2021 -
Vertex begins human testing for diabetes cell therapy
March 10, 2021 -
Acadia shares plunge after unexpected FDA feedback
March 9, 2021